It can't give you the flu. Every injectable version is either killed virus or just the spike protein — nothing that can replicate. The sore arm and next-day low fever are the immune system learning the shape, not a mild infection.
You re-take it yearly because the virus drifts. The strain rewrites itself a little each winter, and your antibodies wane over about six months. Last year's shot doesn't cover this year.
It roughly halves your odds of a confirmed-flu week in a healthy adult 1 — the fever, the body-ache, the three-week tail of fog. In a good-match season effectiveness runs 50 to 60 percent; the H3N2 strain misses more, dropping the average 2.
Which shot you ask for depends on your risk group.
Expect a sore arm for a day or two. Take it in your non-dominant arm so you can still sleep on the other side.
Most of what you get is invisible: the events that didn't happen.
- Days: a sore arm, maybe a mild fever the next morning. Done.
- The winter it pays out: no week of high fever, no three-week tail. Most years you'd have dodged flu anyway, so the win is probabilistic.
- A year out, if you have heart disease: a third fewer cardiac events 4. In heart-attack patients, the IAMI trial found 41 percent lower one-year mortality in the vaccinated arm 5.
The fine print — when to skip it, and what people get wrong
"I got the shot and still got sick." Usually true, usually not flu. RSV, cold coronaviruses, and rhinovirus all run the same months and feel identical; without a swab, most self-reported flu isn't flu.
Why it sometimes underperforms: strains are picked eight months early and H3N2 drifts fastest, so a bad-match year can fall near 19 percent. But protection against severe disease holds up better than against infection — even a mismatched shot usually still keeps you out of hospital.
When to be careful: anaphylaxis to a past flu shot, or Guillain-Barré within six weeks of one, means get the next in a clinical setting and discuss it first. Egg allergy is no longer a special case 3. Sick with a fever that day? Push it a week.
- 1Demicheli et al. (2018). Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews. link
- 2Belongia et al. (2016). Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infectious Diseases. link
- 3Grohskopf et al. (2024). Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024-25 Influenza Season. MMWR Recommendations and Reports. link
- 4Behrouzi et al. (2022). Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis. JAMA Network Open. link
- 5Frobert et al. (2021). Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. link
Seasonal Influenza Vaccine
Free under all ACA-compliant US plans and Medicare Part B; free for at-risk groups and ≥65 in the UK NHS. Out-of-pocket at a pharmacy is $25-90 once per year if uninsured. Trivial by catalogue standards.
A single once-a-year action: 10-20 minutes at a pharmacy, drop-in without appointment in most countries. No prep, no follow-up. Occasional 24-48h arm soreness and low-grade reactogenicity but no time off needed.
Multiple Cochrane reviews (Demicheli et al. 2018), large multi-arm RCTs (DiazGranados et al. 2014 high-dose FIM12; Frobert et al. 2021 IAMI cardiovascular; Dunkle et al. 2017 recombinant), and consistent test-negative-design effectiveness data (Belongia et al. 2016) — the central effect is firmly established. Held back from 5 by genuine season-to-season variability in match and the persistent H3N2 effectiveness gap (~33% pooled VE).
Meaningful disease prevention at the population level: global modelling estimates 290,000-650,000 seasonal flu deaths annually (Iuliano et al. 2018), concentrated in older adults and those with cardiovascular or respiratory comorbidity. The post-MI/CAD subgroup gets the strongest single effect: ~28-34% reduction in major cardiovascular events at one year (Frobert et al. 2021; Behrouzi et al. 2022), on top of mortality reduction in the elderly (DiazGranados et al. 2014).
A real but small expected improvement to a typical year: 40-60% relative reduction in symptomatic, lab-confirmed influenza (Demicheli et al. 2018; Belongia et al. 2016), translating to a ~1-2 percentage-point absolute risk drop in healthy adults — the felt payoff is avoiding 5-7 days of high-fever incapacitation and 1-3 weeks of post-viral fatigue, but only in the years/people who would have gotten sick.